N6-ADENOSINE METHYLTRANSFERASE COMPLEX REGULATOR ZC3H13 DELETION AS MALIGNANT PROGNOSIS FACTOR IN PROSTATE CANCER
Epitranscriptomic and Cancer Lab, Centro de Investigación del Cáncer (CIC)
Alterations of epitranscriptomic marks have been recently associated to several types of cancer, especially 6-methyladedosine (m6A). We find that a 15% of prostate cancer (PCa) patients have deletions in ZC3H13, a regulator of the m6A deposition complex. Its deletion correlates with decreased expression of METTL3, the catalytic unit of the m6A deposition complex, and decreased m6A deposition. Decreased m6A deposition affects the expression of genes that regulate migration and metastasis in PCa, thus, targeting m6A demethylases could be a novel strategy to treat metastatic PCa.